INSTRUCTOR S NOTE. Copyright 2018, The Johns Hopkins University and Teaching Vaccine Economics Everywhere.
|
|
- Catherine May Pearson
- 6 years ago
- Views:
Transcription
1 INSTRUCTOR S NOTE This case study can be used to motivate several learning objectives and can be tied to specific course objectives in the modules. In case studies the students are not spoon-fed. Instead, they have to wade through relevant and irrelevant data and identify ways to organize the facts that matter. The orthodox economic paradigm for comparing multiple policies is supposed to be straightforward comparison of an ICER to a country s willingness to pay to avert a DALY. However, these parameters are seldom available. Instructors can use this case study to bring out the basics of estimating ICERs, data quality, budget impact, and the need to understand decision thresholds. This case study could be introduced early in the course to motivate topic matter. Returning after topics have been covered could help to solidify learning. Economic Evaluation Understand the basic concepts of economic evaluation Determine relevant decision criterion Utilize analysis and apply the findings to compare policy decisions Costing of the program / strategies / treatment Decide what costs to include Decide what outcomes to measure Identify appropriate sources of data on cost and outcomes Learn how to use the ICER curve Understand that the ICER curve requires a budget line Health Economics Viewing how vaccines fit into health system building blocks Understand the difference between marginal, average, and total cost Understand that there is no right answer in determining how much should be spent to save a life Explain opportunity costs, monetary benefits, and health outcomes Apply economic decision making principles to realistic case studies
2 Uganda Measles Case Study Authors: David Bishai and Sasmira Matta Background: What is measles? How is Uganda affected? Measles is an acute viral disease that is characterized by a fever, cough, and conjunctivitis, followed by a rash [1]. Case fatality rates are higher in children younger than 5 years and in immunocompromised children, specifically children with leukemia, human immunodeficiency virus (HIV) infection, and severe malnutrition (including Vitamin A deficiency) [1]. Though the prevalence of measles is declining worldwide, measles still presents itself to be an issue in Africa as the average incidence of confirmed measles was 1.9 per 100,000 of the population in 2009 [2]. The WHO-UNICEF accelerated strategy for reducing measles focuses on 47 priority countries that have the highest measles disease burden Uganda is one of these countries [3]. Compared to the African continent s incidence, Uganda s incidence rate is significantly lower at 0.2 per 100,000 as of 2009 [2]. Similarly, the number of reported cases declined last decade from 5,736 cases in 2006 to 1121 cases in 2014 [4]. Despite this decline, it is still of upmost importance that coverage rates be maintained well above 90% since measles outbreaks will occur at lower coverage levels. Photograph from the Public Health Image Library courtesy of the Center for Disease Control and Prevention and Dr. Lyle Conrad. ID: 6887
3 The purpose of this case study is to examine the six different scenarios as suggested by the WHO Expert Group for maintaining high coverage and to determine the best scenario for Uganda. Key Terms and Important Information: A. Vaccine-Related Acronyms In order to fully understand the following scenarios, it is important to understand acronyms that pertain to the measles vaccination. MCV1 means that a child gets a single shot of the measles vaccines at nine months whereas MCV2 means that the child gets 2 shots of the measles vaccine. While the Center for Disease Control indicates that a single dose of the vaccine is 93% effective, two doses prove to be approximately 97% effective [5]. Since the two-dose course of the vaccination is expensive, low-income countries take the risk of a lower effectiveness and often vaccinate children with only one dose. Moreover, Uganda has Supplemental Immunization Activity (SIA) approximately every three years, which is a national campaign where all children, regardless of vaccination status, are administered a measles vaccine. B. Geography Core areas are areas where the children are easy to reach; satellite areas are areas where the children are difficult to reach. C. Types of Costs Total cost is the summation of all of the costs. Average cost is the total cost divided by the total number of products or services. Marginal cost is the additional cost added by producing one additional unit of a product or service. The marginal cost curve depicts an increasing incurred cost as the number of additional units increases. Typically the marginal cost of immunizing one more child starts to rise before the average cost starts to rise. This is because it can be efficient to immunize the
4 closer children first and then immunize the children who are remote or surrounded by violence later. D. Disability Adjusted Life Years (DALY) A DALY can be thought of as one lost year of healthy life [6]. The sum of the DALYs across a population are indicative of the burden of disease and can be thought of as the gap between current health status and an ideal health situation where the population lives free of disease and disability [6]. Therefore, it is important to note that in eradicating and reducing disease prevalence, the goal is to minimize DALYs. IV. Scenarios As of 2010 The MCV1 coverage rate is 68% of 9 month year olds The MCV2 coverage rate is negligible for 9 month year olds The SIA activity indicates a 90% coverage rate of 9 month olds to 5 year olds The best antibody response occurs if measles vaccine is given after the child is 12 months. However, in high risk areas infants are in too much danger if they wait that long, and it is better to give the first dose MCV1 at 9 months and then follow up with a 2nd dose MCV2 at 36 months. The following scenarios 2 through 6, were determined by the WHO Strategic Advisory Group of Experts to be the most attractive to implement in the year Scenario 1: Maintain baseline coverage Scenario 2: Maintain current levels of coverage activities but no SIAs Scenario 3: 95% Mortality Reduction as compared to 2000 Scale up MCV1 by 3% until 2015 Stop SIA in 2014 Scenario 4: 98% mortality reduction as compared to 2000 Ramp up MCV1 by 20% until 2020 Introduce MCV2 for children aged 36 months in 2018 Stop SIAs in 2017 Scenario 5: Eradication of measles by 2020 Ramp up MCV1 coverage by 3% until 2020 Introduce MCV2 for children aged 36 months in 2016 Stop SIA in 2014 Scenario 6: Eradication of measles by 2025 Ramp up MCV1 coverage by 3% until 2025 Introduce MCV2 for children aged 36 months in 2017 Stop SIA in 2017
5 V. Key Figures and Supporting Information The following figures were determined using a simulation that considered resource assumptions to understand what it would take to achieve a higher coverage [7]. Thus these numbers reflect the increased number of community health workers, the number of hours required to reach the children, and expensive logistics[8]. Achieving a higher coverage rate involves more resources, which is more expensive. The average cost per child vaccinated is $1 prior to scale up via routine services The scale up cost per child for core areas is $27 The scale up cost per child for satellite areas is $36 The scale up cost per child for MCV2 in core areas is $9 The scale up cost per child in MCV2 in satellite areas is $27 The SIA cost per child is $.60 Infant mortality from measles is twice as high as that of toddlers and four times as high as that of children and adults The model assumes that children can be easy to reach (i.e. in core areas) or hard to reach (i.e. in satellite areas ) The scale up costs vary between the children in core vs. satellite areas because the kids that have not been reached are harder to vaccinate simply because they are harder to find. Therefore, finding them requires more resources, which translates to more money. Figure III. Costs Associated With Each Scenario
6 Figure IV. Costs vs. Measles DALYs in Uganda for the 6 Scenarios. Incremental Cost Effectiveness Ratios (ICERS) are Interpreted as $ per DALY Averted. Note: The green triangle indicates Scenario 3, which would cost between million dollars to achieve 1.3 million discounted DALYS. VI. Moving Forward The big decision underlying how to proceed in order to maximally boost coverage cannot be answered until a number of smaller decisions are made. Let us suppose that all of the data are going to be presented, and you have the role of the chief of the EPI program. As state above, remember that DALYS are bad they are disability weighted years of life lost. A country wants to have as few of these as possible. Costs, as you already know are also something a country wants less of.
7 Questions: 1) What will you consider in order to pick among the six policies? What matters here? In other words what are important decision criterion to consider? 2) Which scenario would you select to minimize cost? 3) Which scenario would you select to maximize benefit? 4) Which scenario yields the most attractive ICER? 5) How intensive are you going to get your coverage? What are the costs of this? What are the benefits?
8 6) When are you going to drop the SIAs? 7) How much should be spent to save a life? 8) Given the data in this document, what other things do you wish you knew? 9) What alternative options are there to increase coverage? List the pros and cons for each option. 10) Specifically delineate how you are using the cost information to drive decisions.
9 Works Cited 1. Pediatrics, A.A.o., Red Book: 2015 Report of the Committee on Infectious Diseases, B.M. Kimberlin DW, Jackson MA, Long SS, Editor. 2015, American Academy of Pediatrics. p Organization, W.H., AFRO Measles Surveillance Feedback Bulletin UNICEF, W.H.O.a., Measles Mortality Reduction and Regional Elimination Strategic Plan : Geneva. 4. Organization, W.H., Reported measles cases and incidence rates by WHO Member States 2013, 2014 as of 11 February National Center for Immunization and Respiratory Diseases, D.o.V.D. Measles Vaccination. Measles (Rubeloa) 2016 November 22, Organization, W.H. Metrics: Disability-Adjusted Life Year (DALY). Health statistics and information systems. 7. Bishai, D., et al., The cost-effectiveness of supplementary immunization activities for measles: a stochastic model for Uganda. J Infect Dis, Suppl 1: p. S Bishai, D., et al., Technical Appendix for Measles eradication versus measles control: an economic analysis. J Infect Dis, Suppl 1: p. S
Financing Understand how budgets are developed Understand the value of budget impact, factor affordability into decision making
Instructor s Note This case study can be used to motivate several learning objectives and tied to specific course objectives in the modules. In case studies the students are not spoon fed. They have to
More informationUnderstanding Vaccine Economics with Simulations Authors: David Bishai and Sasmira Matta
Understanding Vaccine Economics with Simulations Authors: David Bishai and Sasmira Matta Learning Objectives: To understand the Philipson effect or how the acceptability of a vaccine is determined To understand
More informationIntroduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa
Introduction to Measles a Priority Vaccine Preventable Disease (VPD) in Africa Nigeria Center for Disease Control Federal Ministry of Health Abuja July 2015 Outline 1. Measles disease 2. Progress towards
More informationEconomic Evaluation. Introduction to Economic Evaluation
Economic Evaluation Introduction to Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationEconomic Consequences of an Infectious Disease Event for a Small, Island Economy
National Center for Immunization & Respiratory Diseases Economic Consequences of an Infectious Disease Event for a Small, Island Economy Jamison Pike, MS, PhD Prevention Effectiveness Fellow Society for
More informationGlobal reductions in measles mortality and the risk of measles resurgence
Global reductions in measles mortality 2000 2008 and the risk of measles resurgence Measles is one of the most contagious human diseases. In 1980 before the use of measles vaccine was widespread, there
More informationIn the Name of God, the Compassionate, the Merciful. Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION.
In the Name of God, the Compassionate, the Merciful Address by DR HUSSEIN A. GEZAIRY REGIONAL DIRECTOR WHO EASTERN MEDITERRANEAN REGION on the FIRST EMIRATES INTERNATIONAL CONFERENCE ON VACCINATION Dubai,
More informationMeasles Strategic Planning Tool: Analysis of MCV strategies in developing countries. Emily Simons 29 January 2009
Measles Strategic Planning Tool: Analysis of MCV strategies in developing countries Emily Simons 29 January 2009 Overview The MSP tool Results by question For Indian states: what is best strategy to accelerate
More informationStudy population The study population comprised the general population of Senegal inhabitants aged 1 to 30 years.
Comparison of cost-effectiveness of preventive and reactive mass immunization campaigns against meningococcal meningitis in West Africa: a theoretical modeling analysis Parent du Chatelet I, Gessner B
More information5 $3 billion per disease
$3 billion per disease Chapter at a glance Our aim is to set a market size large enough to attract serious commercial investment from several pharmaceutical companies that see technological opportunites,
More informationMeasles and Rubella Global Update SAGE 19 October 2017
Measles and Rubella Global Update SAGE 19 October 2017 Alya Dabbagh WHO HQ, IVB/EPI Global update Overview Regional progress and challenges M&RI Midterm Review updates Economics of measles and rubella
More informationTitle of the presentation
. Title of the presentation Economic analyses for hepatitis elimination Subtitle of the presentation, lorem ipsum dolor sit amet. Yvan Hutin, Global Hepatitis Programme, World Health Organization November
More informationExisting approaches to costing, financing and estimating cost-efficiencies for nutrition
Existing approaches to costing, financing and estimating cost-efficiencies for nutrition February 2016 Meera Shekar Global Lead for Nutrition 1 Global Stunting Rates 159 million children stunted worldwide
More informationInternational PolioPlus Committee PolioPlus Facts and Figures June Rotary s financial contribution to the polio eradication effort:
International PolioPlus Committee PolioPlus Facts and Figures June 2018 1. The goal of the PolioPlus program: The goal of the PolioPlus program is the global certification of polio eradication. By eradication,
More informationHow does Gavi make vaccine investment decisions?
How does Gavi make vaccine investment decisions? Judith Kallenberg Global Vaccine and Immunization Research Forum Johannesburg, South-Africa, 16 March 2016 www.gavi.org Vaccine Investment Strategy (VIS)
More informationJANUARY One Shot, One Life Saved. Measles Initiative Saves a Child for $1
WWW.LIONSCLUBS.ORG JANUARY 2012 One Shot, One Life Saved Measles Initiative Saves a Child for $1 ONE SHOT, THE LIONS MEASLES INITIATIVE SAVES A LIFE FOR LESS THAN $1 Randrianarisoa Hariliva, a midwife
More informationPapillomavirus Rapid Interface for Modelling and Economics Tool. User Manual
Papillomavirus Rapid Interface for Modelling and Economics Tool User Manual List of abbreviations DALYs disability adjusted life years GDP HPV IARC gross domestic product human papillomavirus International
More informationMeasles and Rubella Initiative Outbreak Response Fund Standard Operating Procedures, effective 01 April 2017
Measles and Rubella Initiative Outbreak Response Fund Standard Operating Procedures, effective 01 April 2017 A. Introduction In June 2012, the Gavi Board approved $55 million US for measles outbreak response
More informationPrimer on Simulation Modeling: Using Model-Based Analyses to Inform Health Policy and Research on HIV Prevention
Primer on Simulation Modeling: Using Model-Based Analyses to Inform Health Policy and Research on HIV Prevention Caitlin Dugdale, MD Massachusetts General Hospital Global HIV Vaccine Enterprise Modeling
More informationSensitivity and Positive Predictive Value of the Measles Surveillance System In Uganda,
Public Health Fellowship Program Field Epidemiology Track Sensitivity and Positive Predictive Value of the Measles Surveillance System In Uganda, 2012-2015 Dr.Fred Nsubuga, MBChB, MPH Fellow, Cohort 2015
More informationSUPPLEMENTARY APPENDICES FOR ONLINE PUBLICATION. Supplement to: All-Cause Mortality Reductions from. Measles Catch-Up Campaigns in Africa
SUPPLEMENTARY APPENDICES FOR ONLINE PUBLICATION Supplement to: All-Cause Mortality Reductions from Measles Catch-Up Campaigns in Africa (by Ariel BenYishay and Keith Kranker) 1 APPENDIX A: DATA DHS survey
More informationSPECIAL EVENT ON PHILANTHROPY AND THE GLOBAL PUBLIC HEALTH AGENDA. 23 February 2009, United Nations, New York Conference Room 2, 3:00 p.m. 6:00 p.m.
SPECIAL EVENT ON PHILANTHROPY AND THE GLOBAL PUBLIC HEALTH AGENDA 23 February 2009, United Nations, New York Conference Room 2, 3:00 p.m. 6:00 p.m. ISSUES NOTE Improving the Health Outcomes of Women and
More informationResponse to HIV LOGISTICAL AND OTHER PERSPECTIVES
Response to HIV LOGISTICAL AND OTHER PERSPECTIVES Margaret Brandeau Department of Management Science and Engineering Department of Medicine Stanford University Topics HIV: A humanitarian crisis Planning
More informationStudy population The study population comprised HIV-infected pregnant women seeking antenatal care.
Cost-effectiveness of nevirapine to prevent mother-to-child HIV transmission in eight African countries Sweat M D, O'Reilly K R, Schmid G P, Denison J, de Zoysa I Record Status This is a critical abstract
More informationUNIVERSITY OF CALGARY. Cost-effectiveness of chest x-ray screening for diagnosis and treatment of inactive. Dina Avalee Fisher A THESIS
UNIVERSITY OF CALGARY Cost-effectiveness of chest x-ray screening for diagnosis and treatment of inactive pulmonary tuberculosis in a high-incidence country by Dina Avalee Fisher A THESIS SUBMITTED TO
More informationDr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya
Dr. Collins Tabu KPA Conference, 26 th April 2018 Mombasa, Kenya Presentation Outline Background Immunization Performance review Available Opportunities for engagement Planned and ongoing strategies- New
More informationSustaining Immunization in Developing Countries: The Future We Make
Sustaining Immunization in Developing Countries: The Future We Make Global Health Summit Denver, CO 29 April 211 Jon Kim Andrus, MD Deputy Director Umbrella of protection in the Americas Measles eradication
More informationGOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights
GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION (indicator G2.2) Highlights As of December 2014, 140 Member States had introduced rubella vaccines; coverage, however, varies from 12% to 94% depending on region.
More informationGavi s Vaccine Investment Strategy
Gavi s Vaccine Investment Strategy Judith Kallenberg, Head of Policy WHO Product Development for Vaccines Advisory Committee Meeting Geneva, Switzerland, 7-9 September 2015 www.gavi.org Vaccine Investment
More informationEconomic Evaluation of Measles Eradication Study: Results for Six Countries and by Income Groups
Economic Evaluation of Measles Eradication Study: Results for Six Countries and by Income Groups Prepared for: World Health Organization Ann Levin1, Colleen Burgess2, Louis Garrison3, Chris Bauch4, Joseph
More informationExpanded Programme on Immunization
Expanded Programme on Immunization Expanded Programme on Immunization has been implementing the reduction of morbidity and mortality due to vaccine preventable diseases among the children aged 1 to 5 years
More informationSimplifying pediatric immunization with a fully liquid pentavalent vaccine: Evidence from a time-motion study
Simplifying pediatric immunization with a fully liquid pentavalent vaccine: Evidence from a time-motion study Dr. Karin Anne Wiedenmayer Swiss Tropical Institute Basel, Switzerland February 2008 1 Value
More informationCenters for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC,
Centers for Disease Control and Prevention (CDC) Coalition C/o American Public Health Association 800 I Street NW Washington, DC, 20001 202-777-2514 Donald Hoppert, Director of Government Relations, American
More informationDISCLOSURES. I have no actual or potential conflicts of interest in this presentation.
OVERVIEW ON MEASLES Oneka B. Marriott, DO, MPH, FAAP, FACOP Assistant Professor of Pediatrics and Public Health Nova Southeastern University College of Osteopathic Medicine Presentation to FSACOFP Annual
More informationCost effectiveness of measles eradication. Final Report. August 12, David Bishai, MD, MPH, PhD Benjamin Johns Amnesty Lefevre Divya Nair
Cost effectiveness of measles eradication Final Report August 12, 2010 David Bishai, MD, MPH, PhD Benjamin Johns Amnesty Lefevre Divya Nair Johns Hopkins Bloomberg School of Public Health Acknowledgments
More informationCost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J
Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-saharan Africa Marseille E, Kahn J G, Saba J Record Status This is a critical abstract of an economic evaluation
More informationWEB ANNEX I. REPORT ON COST-EFFECTIVENESS OF IMPLEMENTING AN INDETERMINATE RANGE FOR EARLY INFANT DIAGNOSIS OF HIV
WEB ANNEX I. REPORT ON COST-EFFECTIVENESS OF IMPLEMENTING AN INDETERMINATE RANGE FOR EARLY INFANT DIAGNOSIS OF HIV In: Updated recommendations on first-line and second-line antiretroviral regimens and
More informationTying it all together health economic modeling
Tying it all together health economic modeling Ruanne V Barnabas, MD, DPhil Associate Professor, Global Health, Allergy & Infectious Disease University of Washington How models can be used with cost-effectiveness
More informationRole of Economic Epidemiology: With Special Reference to HIV/AIDS
Role of Economic Epidemiology: With Special Reference to HIV/AIDS Senelani Dorothy Hove-Musekwa NUST AIMS Bulawayo Cape Town Zimbabwe South Africa Economic Epidemiology Workshop - Uganda: 3 August 2009
More informationReport to the Board June 2015
10-11 June 2015 SUBJECT: Report of: Authored by: Agenda item: Category: MEASLES SUPPLEMENTARY IMMUNISATION ACTIVITIES Hind Khatib-Othman, Managing Director, Country Programmes Khin Devi Aung, Senior Programme
More informationMeasles 2015: What We Need to Know
Faculty Measles 2015: What We Need to Know Karen Landers, MD, FAAP Assistant State Health Officer Tuberculosis Control and Immunization Alabama Department of Public Health Produced by the Alabama Department
More informationBack to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office
Back to Basics: Regional Progress Towards Measles and Rubella Elimination and Introduction of New Vaccines WHO European Regional Office SAGE, Geneva 27 October 2009 Rebecca Martin Targeted Diseases and
More informationCopenhagen, Denmark, September August Malaria
Regional Committee for Europe 64th session EUR/RC64/Inf.Doc./5 Copenhagen, Denmark, 15 18 September 2014 21 August 2014 140602 Provisional agenda item 3 ORIGINAL: ENGLISH Malaria Following the support
More informationCritical immunity thresholds for measles elimination
Critical immunity thresholds for measles elimination Sebastian Funk Centre for the Mathematical Modelling of Infectious Diseases London School of Hygiene & Tropical Medicine 19 October, 2017!"vöå"!(}å!öZ&!
More informationb de HPV Vaccination of School-Age Girls comparing the cost-effectiveness of 3 delivery programmes SUMMARY
b de HPV Vaccination of School-Age Girls comparing the cost-effectiveness of 3 delivery programmes SUMMARY Human papillomaviruses (HPV) are common sexually transmitted viruses. They can cause several types
More informationMeasles Incidence and Secular Trend over the Last Five Years, Pre and Post Massive Population Based Vaccination
International Journal of Biomedical and Clinical Sciences Vol. 2, No. 4, 2017, pp. 32-36 http://www.aiscience.org/journal/ijbcs Measles Incidence and Secular Trend over the Last Five Years, Pre and Post
More informationMeasles-Containing Vaccines: Supply & Demand Outlook. UNICEF Supply Division
MeaslesContaining Vaccines: & Outlook UNICEF Division May 2014 0 MeaslesContaining Vaccines (MCV): & Outlook May 2014 This update reports on anticipated 2014 MCV demand and supply availability. Unconfirmed
More informationCost-effectiveness of a pediatric dengue vaccine Shepard D S, Suaya J A, Halstead S B, Nathan M B, Gubler D J, Mahoney R T, Wang D N, Meltzer M I
Cost-effectiveness of a pediatric dengue vaccine Shepard D S, Suaya J A, Halstead S B, Nathan M B, Gubler D J, Mahoney R T, Wang D N, Meltzer M I Record Status This is a critical abstract of an economic
More informationAn exploration of the cost-effectiveness of interventions to reduce. differences in the uptake of childhood immunisations in the UK using
An exploration of the cost-effectiveness of interventions to reduce differences in the uptake of childhood immunisations in the UK using threshold analysis National Collaborating Centre for Women s and
More informationImproving efficiency in health. Hepatitis C virus session
Improving efficiency in health Hepatitis C virus session Aims of this session Optima is a tool to assist in reducing the burden of diseases by optimizing resource allocation. This session will discuss:
More information1980 Eradication Ended Vaccinations
Smallpox Basics The Politics of Smallpox Modeling Rice University - November 2004 Edward P. Richards, JD, MPH Director, Program in Law, Science, and Public Health Harvey A. Peltier Professor of Law Louisiana
More informationCost Effectiveness of New Diagnostics for TB
Cost Effectiveness of New Diagnostics for TB David Bishai, Megan O Brien, David Dowdy Johns Hopkins University October 10, 2007 Outline Objectives What combinations of sensitivity and price would result
More informationMeeting of the Polio Oversight Board (call) 1 September :00 am 11:00 am Meeting Minutes
Participants: Dr. Tom Frieden (CDC, POB Chair) Mr. John Germ (Rotary) Dr. Chris Elias (BMGF) Dr. Margaret Chan (WHO) Mr. Tony Lake (UNICEF) Meeting of the Polio Oversight Board (call) 1 September 2016
More informationCONTRACEPTIVES SAVE LIVES
CONTRACEPTIVES SAVE LIVES Updated with technical feedback December 2012 Introduction In the developing world, particularly in Sub-Saharan Africa and South Asia, progress in reducing maternal and newborn
More informationEpidemiology of measles in infants younger than 6 months: analysis of surveillance data
Epidemiology of measles in infants younger than 6 months: analysis of surveillance data 2011-2016 An analysis of the epidemiology of measles in infants younger than 6 months was conducted by the U.S. CDC
More informationWHO Consultation on universal access to core malaria interventions in high burden countries: main conclusions and recommendations
WHO Consultation on universal access to core malaria interventions in high burden countries: main conclusions and recommendations 12-15 February 2018 Salle XI, ILO Building, Geneva, Switzerland Country
More informationARTICLE IN PRESS Vaccine xxx (2010) xxx xxx
Vaccine xxx (2010) xxx xxx Contents lists available at ScienceDirect Vaccine journal homepage: www.elsevier.com/locate/vaccine Economic analysis of the global polio eradication initiative Radboud J. Duintjer
More informationCONTENTS. Paragraphs I. BACKGROUND II. PROGRESS REPORT ON THE AFRICAN REGIONAL IMMUNIZATION STRATEGIC PLAN
23 September 2013 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-third session Brazzaville, Republic of Congo, 2 6 September, 2013 Agenda item 14 IMMUNIZATION IN THE AFRICAN REGION: PROGRESS REPORT
More informationmeasles? Abstract Introduction JUNE 2017 routine vaccination to 1 year old babies, and the second dose to
December JUNE 2017 2018 causes brains How canwhat we keep thelizards world free of to change size? measles? Authors: Authors: Susan Crow, Meghan Pawlowski, Manyowa Meki, Joaquin Prada, Jess Metcalf, Lara
More informationColloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention
Colloque scientifique : L économie de la prévention Analysis of Cost-Effectiveness of HIV Prevention Julia Walsh MD, MSc Professor School of Public Health University of California Berkeley Objectives Cost-effectiveness
More informationMessage from. Dr Samlee Plianbangchang Regional Director, WHO South-East Asia. At the. Regional Review Meeting on Immunization
Message from Dr Samlee Plianbangchang Regional Director, WHO South-East Asia At the Regional Review Meeting on Immunization 19-23 July 2010 WHO/SEARO, New Delhi Regional Review Meeting on Immunization
More informationSenior Project Proposal Abby Conn October 23, 2018
Senior Project Proposal Abby Conn October 23, 2018 I. Title of Project: Designing an Early Warning System for Pediatric Sepsis Detection at Northern Arizona Healthcare (NAH) II. Statement of Purpose: Sepsis
More informationUpdated WHO position paper on pertussis vaccines. Geneva, Switzerland October 2010
Updated WHO position paper on pertussis vaccines Geneva, Switzerland October 2010 Introduction Replaces the position paper on pertussis vaccines published in the Weekly Epidemiological Record in January
More informationVaccines. Global impact of a preventive technology. Edwin J. Asturias, MD
Vaccines Global impact of a preventive technology Edwin J. Asturias, MD Associate Professor of Pediatrics and Epidemiology Director for Latin America Center for Global Health, Colorado School of Public
More informationMs. Gaye Phillips, Representative, UNICEF Malaysia, Mr. Kiyoshi Nakamitsu, Programme Officer, UNICEF Malaysia, Distinguished Guests,
SPEECH BY YB DATO DR. CHUA SOI LEK, MINISTER OF HEALTH MALAYSIA, AT THE ANNOUNCEMENT OF THE PROGRESS FOR CHILDREN GLOBAL REPORT, AT WISMA UN, DAMANSARA HEIGHTS, KUALA LUMPUR, ON 18 NOV 2004 AT 10.30 AM
More informationGAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS
GAVI ALLIANCE: UPDATE AND FUTURE DIRECTIONS FOR GLOBAL VACCINES AND IMMUNISATIONS Ranjana Kumar International Rotavirus Symposium Istanbul, 3 4 June 2008 The GAVI Alliance Public-private partnership bringing
More informationNO MORE MISSED MDG4 OPPORTUNITIES: OPTIMIZING EXISTING HEALTH PLATFORMS FOR CHILD SURVIVAL. Measles & Rubella Campaigns
NO MORE MISSED MDG4 OPPORTUNITIES: OPTIMIZING EXISTING HEALTH PLATFORMS FOR CHILD SURVIVAL Measles & Rubella Campaigns With fewer than 600 days remaining to the Millennium Development Goal (MDG) deadline,
More informationHere s a list of the Behavioral Economics Principles included in this card deck
Here s a list of the Behavioral Economics Principles included in this card deck Anchoring Action Goals Availability Bias Decision Paralysis Default Bias Disposition Effect Ego Depletion Endowment Effect
More informationEx post evaluation Tanzania
Ex post evaluation Tanzania Sector: Health, family planning, HIV/AIDS (12250) Project: Promotion of national vaccination programme in cooperation with GAVI Alliance, Phase I and II (BMZ no. 2011 66 586
More informationChapter 8 notes Human Capital: Education and Health (rough notes, use only as guidance; more details provided in lecture)
Chapter 8 notes Human Capital: Education and Health (rough notes, use only as guidance; more details provided in lecture) education and health are basic objectives of development but also important goals
More informationHEALTHCARE DESERTS. Severe healthcare deprivation among children in developing countries
HEALTHCARE DESERTS Severe healthcare deprivation among children in developing countries Summary More than 40 million children are living in healthcare deserts, denied the most basic of healthcare services
More informationReporting and Interpreting Results of Economic Evaluation
Reporting and Interpreting Results of Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationUpdate on Vaccine Recommendations. Objectives. Childhood Immunization Schedule At the Turn of the Century. New Horizons in Pediatrics April 30, 2017
Centers for for Disease Disease Control Control and and Prevention Prevention National Center for Immunization and Respiratory Diseases Update on Vaccine Recommendations New Horizons in Pediatrics April
More informationFolland et al Chapter 4
Folland et al Chapter 4 Chris Auld Economics 317 January 11, 2011 Chapter 2. We won t discuss, but you should already know: PPF. Supply and demand. Theory of the consumer (indifference curves etc) Theory
More informationPolio and measles control: opportunities and threats for health systems
Polio and measles control: opportunities and threats for health systems USAID Global Health Mini University March 4, 2016 Dr. Craig Burgess, JSI OVERVIEW Polio and measles: an overview Control strategies
More information2007 ACIP Recommendations for Influenza Vaccine. Anthony Fiore, MD, MPH Influenza Division, NCIRD, CDC
2007 ACIP Recommendations for Influenza Vaccine Anthony Fiore, MD, MPH Influenza Division, NCIRD, CDC National Influenza Vaccine Summit April 19, 2007 Recommendation Changes for Influenza Vaccination:
More informationSTATEMENT OF LYNN STRATFORD SENIOR VICE PRESIDENT, PROGRAM AND COMMUNITY ENGAGEMENT UNITED STATES FUND FOR UNICEF
STATEMENT OF LYNN STRATFORD SENIOR VICE PRESIDENT, PROGRAM AND COMMUNITY ENGAGEMENT UNITED STATES FUND FOR UNICEF BEFORE THE SUBCOMMITTEE ON STATE, FOREIGN OPERATIONS, AND RELATED PROGRAMS COMMITTEE ON
More informationReport to the Board 6-7 June 2018
6-7 June 2018 SUBJECT: VACCINE INVESTMENT STRATEGY: SHORT LIST Agenda item: 07 Category: For Decision Section A: Introduction This report presents outcomes of the Phase II analyses for the Vaccine Investment
More informationYellow Fever Vaccine: Current Outlook. UNICEF Supply Division
Yellow Fever Vaccine: Current Outlook UNICEF Supply Division March 2015 0 Yellow Fever Vaccine - Current Outlook March 2015 This update provides revised information on the continued constrained 2014-2017
More informationIncluding Health Economics in Your Specific Aims and Approach
Including Health Economics in Your Specific Aims and Approach Ruanne V Barnabas, MD, DPhil Health Economics Impact Study Team (HEIST) Center for AIDS Research (CFAR) Outline Background Specific Aims Approach
More informationCenter for Global Health. CDC Global Health Saving Lives Overseas, Protecting Americans at Home
Center for Global Health CDC Global Health Saving Lives Overseas, Protecting Americans at Home CDC Overview Part of the U.S. Department of Health and Human Services, CDC is the nation s leading public
More informationFor information on programmes in other countries and regions please access the Federation website at Programme title 2005
POLIO AND MEASLES Appeal no. 5AA89 Appeal target: CHF 3,52,674 1 The International Federation's mission is to improve the lives of vulnerable people by mobilizing the power of humanity. The Federation
More informationDisability-Adjusted Life Year conversion
Disability-Adjusted Life Year conversion CASE STUDY #1: HIV CASES TO DALYS Joanna Emerson, MPH, David Kim, PhD AIM This study aims to convert disease-specific health outcomes (e.g., HIV cases) reported
More informationSHOULD VACCINES BE COMPULSORY?
The Big Debate SHOULD VACCINES BE COMPULSORY? Friday 02 March 2018 SHOULD VACCINES BE COMPULSORY? THE DILEMMA A change in French law means that all parents must now vaccinate children born on 1 January
More informationPrince Albert Parkland Regional Health Authority Immunization coverage
Prince Albert Parkland Regional Health Authority Immunization coverage Introduction...91 Background...91 Our audit objective, conclusion, and recommendations...92 Our findings by criteria...93 Promote
More informationOverview. Vaccine innovation With people, for people: The (A) citizens' view. Vaccine impact in perspective. Vaccine research in perspective
Overview Vaccine innovation With people, for people: The (A) citizens' view Disclaimer about the citizen Ending AIDS? A history lesson A way forward hopefully Mitchell Warren Executive Director, AVAC 12
More informationACCTG 533, Section 1: Module 2: Causality and Measurement: Lecture 1: Performance Measurement and Causality
ACCTG 533, Section 1: Module 2: Causality and Measurement: Lecture 1: Performance Measurement and Causality Performance Measurement and Causality Performance Measurement and Causality: We ended before
More informationPreparing for the withdrawal of all oral polio vaccines (OPVs): Replacing trivalent OPV with bivalent OPV
Preparing for the withdrawal of all oral polio vaccines (OPVs): Replacing trivalent OPV with bivalent OPV Frequently Asked Questions February 2015 Table of Contents Rationale for OPV cessation... 2 About
More informationVACCINE MARKETS OVERVIEW SESSION
VACCINE MARKETS OVERVIEW SESSION Robyn Iqbal Program Officer, Vaccine Delivery Market Dynamics UNICEF SD Manufacturers Meeting Copenhagen October 8, 2014 DRAFT Bill & Melinda Gates Foundation DISCUSSION
More informationChild mortality in ACP countries: getting to zero? Simon Wright President, Global Health Advocates
Child mortality in ACP countries: getting to zero? Simon Wright President, Global Health Advocates Latest estimates Substan(al progress made towards achieving MDG 4. 12.6 million in 1990 to 6.6 million
More informationFlour Fortification Initiative
Effectiveness, Safety and Economics of Fortifying Flour with Folic Acid The Flour Fortification Initiative (FFI) encourages countries to add folic acid to flour to reduce the rate of major birth defects
More informationAppendix A: Disease-Specific Chapters
Ministry of Health and Long-Term Care Infectious Diseases Protocol Appendix A: Disease-Specific Chapters Chapter: Haemophilus influenzae disease, all types, invasive Effective: May 2018 Haemophilus influenzae,
More informationANNEX Page. AFR/RC61/11 4 July 2011 ORIGINAL: ENGLISH REGIONAL COMMITTEE FOR AFRICA
4 July 2011 REGIONAL COMMITTEE FOR AFRICA ORIGINAL: ENGLISH Sixty-first session Yamoussoukro, Côte d Ivoire, 29 August 2 September 2011 Provisional agenda item 16 PROGRESS REPORT ON POLIOMYELITIS ERADICATION
More informationDisease Control Priorities. Presentation Sub-title Seventh International Rotavirus Symposium Lisbon June 12, 2006
Disease Control Priorities and Rotavirus Presentation Vaccines Title Presentation Sub-title Seventh International Rotavirus Symposium Lisbon June 12, 2006 1 What is the DCPP? DCPP is an alliance of organizations
More informationRESULTS OF A STUDY ON IMMUNIZATION PERFORMANCE
INFLUENZA VACCINATION: PEDIATRIC PRACTICE APPROACHES * Sharon Humiston, MD, MPH ABSTRACT A variety of interventions have been employed to improve influenza vaccination rates for children. Overall, the
More informationModelling and Simulation in Public Health
Modelling and Simulation in Public Health Margaret Brandeau Department of Management Science and Engineering Stanford University My talk today Need for analysis Four modeling/simulation studies Disease
More informationMalaria Vaccine Implementation Programme Framework for Policy Decision
Malaria Vaccine Implementation Programme Framework for Policy Decision Mary J Hamel, IVR SAGE 17 April 2018 1 Questions for SAGE on the Framework for Policy Decision 1. Does SAGE agree with the approach?
More informationAll About Vaccines and How They Get to Those Who Need Them Most. Elesha Kingshott
All About Vaccines and How They Get to Those Who Need Them Most Elesha Kingshott Shot@Life Four Priority Disease Areas 1. Polio 2. Measles 3. Diarrheal Disease 4. Pneumonia Polio is caused by a virus that
More informationSanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines
Sanofi Pasteur: A partner in eradicating vaccine preventable diseases and improving access to vaccines 1 Vaccines: the single most effective medical intervention 2 Vaccines save lives Millions of cases
More informationDr. Collins Tabu 24 th April 2018 Nairobi, Kenya
Dr. Collins Tabu 24 th April 2018 Nairobi, Kenya Immunization in the developing world Every year, millions of children in poor countries die from preventable diseases because they do not have access to
More information